Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC

Prior treatment

• Received antitumor chemotherapy, radiation therapy, and immunotherapy prior to first treatment.
• Patients with prior or concomitant history of other tumors (except basal cell carcinoma of the skin, cervical cancer in situ).
• Patients with autoimmune disease or immunodeficiency treated with immunosuppressive drugs;
• Substance abuse or those who are unable to undergo immunization or lysosomal viral therapy due to clinical, psychological, or social factors.

Other illness

• Patients with comorbid severe pancreatic portal hypertension, which may cause a higher risk of bleeding with subsequent injection therapy;
• Serious uncontrolled medical conditions that may interfere with the subject's ability to receive treatment as specified in the protocol, including, but not limited to, positive HIV test, active tuberculosis, and DNA copy number of HBV \>103/ml;
• Uncontrollable comorbidities, including, but not limited to, active bacterial, viral, tuberculosis, or fungal infection, symptomatic congestive heart failure, unstable angina, and cardiac arrhythmia.
• Those who may be allergic to the study drug or any of its excipients;

Other

• Pregnant or lactating women;
• Preoperative ultrasound evaluation of patients with small tumor size, location near or behind major blood vessels, and various other factors that may result in a low success rate of intra-tumoral viral injection under ultrasound and a high rate of post-injection complications;
• Any uncertainty that affects patient safety or compliance.

• \- Age ≥18 years and age ≤75 years. ECOG score 0-1. Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer
• Adequate bone marrow and organ function:
• Patients of childbearing potential must take appropriate precautions prior to enrollment and during the study.
• Signed informed consent. Ability to comply with the study protocol and follow-up.